Mean weight loss (1,2)

Similar to natural GLP-1 hormone which acts as a physiological regulator of appetite (1,4)

Patients globally have used Saxenda®(5)

Patients with pre-diabetes returned to normal glycaemic status (1)

1

Saxenda® [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S; September 2020

2

Pi-Sunyer X, Astrup A, Fujioka K, et al. for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med.2015;373(1):11-22.

3

Flint A, Raben A, Astrup A, Holst.JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520. Doi: 10.1172/JCI990

4

Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide corelates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996; 31(7): 665-670.

5

Data on file: IQVIA Data Disclose Appendix 1 2020 supported by internal calculations by Novo Nordisk based on Novo Nordisk ex-factory volume sales by month (Data until 31st Dec’ 19)

6

Marso SP, Daniels GH, Brown-Frandsen K, et al. the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 ; 375(4) : 311-322